MDT
Medtronic plc (NYSE: MDT) announced that it will report financial results on Tuesday, September 1, 2026,...
Article Summary
BUY- Medtronic plc (NYSE: MDT) announced that it will report financial results on Tuesday, September 1, 2026, for its first quarter of fiscal year 2027, which ends on Friday, July 31,2026.
- Medtronic, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions, uniting a global team of 95,000+ passionate people across more than 150 countries.
- Its technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more, powered by diverse knowledge, insatiable curiosity, and desire to help all those who need it.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 8.4% | 25% | 35.0 ptsBelow Screener (8.4%) - Weak growth |
| EPS Growth Next 5Y ? | 7.8% | 25% | 20.0 ptsWeak (7.8%) - Low expectations |
| Target Price Upside ? | 16.1% | 20% | 60.0 ptsModerate Upside (16.1%) - Target: $96.70 vs Current: $83.30 |
| Gross Margin % ? | 60.3% | 15% | 80.0 ptsVery Healthy (60.3%) - High-quality margins |
| Drawdown from 52-Wk High ? | -21.7% | 15% | 40.0 ptsMild Pullback (-21.7%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About MDT
- Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
- It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio.
- The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
- It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products.
- The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name.
- This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments.
- The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors.
- Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.